Danis Pharma
ActiveSummary
Danis Pharma has been active since 1999 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €784,088 and a net result of €71,707. Equity is growing by ~15.3% per year across the filed fiscal years. Its solvency ranks better than 95% of 12,456 sector peers (NACE 47, fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Directors
Owners and capital
Owners
1 ownerChain of control
- Maasdender
- Danis Pharma
Highest known parent: Maasdender. The sources do not say who stands above it.
Owners 1
- Maasdenderparent98.8%
According to the annual accounts of the companies, the acts in the Belgian Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Companies Code and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.